CTOs on the Move

Intra-Cellular Therapies

www.intracellulartherapies.com

 
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Newlink Genetics

NewLink Genetics is a biopharmaceutical company focused on discovering, developing, and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. Founded more than 15 years ago, NewLink Genetics continues to be at the forefront in immuno-oncology treatments led by a diverse group of industry professionals and physician-scientists. Personal cancer stories inspire our relentless research and development in advancing treatments. Our grand passion is to change the cancer treatment paradigm and make a difference in patient lives every day.

Amolyt Pharma

Amolyt Pharma is building on its team`s established expertise in therapeutic peptides development to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases. Amolyt Pharma`s programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. The collaborative Amolyt Pharma team is well-equipped for upcoming milestones and for the adoption of additional programs as made possible by its global network in the field of endocrinology and with support from a strong syndicate of international investors.

Avadel

Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to develop differentiated pharmaceutical products that are safe, effective and easy to take, helping patients adhere to their prescribed medical treatment and see better results. Avadel`s current portfolio of products and product candidates focuses on the urology, central nervous system (CNS) / sleep, and hospital markets. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.

Diffusion Pharmaceuticals

Neuralink is a team of exceptionally talented people. We are creating the future of brain-machine interfaces: building devices now that will help people with paralysis and inventing new technologies that will expand our abilities, our community, and our world. Our goal is to build a system with at least two orders of magnitude more communication channels (electrodes) than current clinically-approved devices. This system needs to be safe, it must have fully wireless communication through the skin, and it has to be ready for patients to take home and use on their own. Our device, called the Link, will be able to record from 1024 electrodes and is designed to meet these criteria.

Medsite

Medsite is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.